Gazzard BG - Search Results

1

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.

Gazzard BG, Pozniak AL, Rosenbaum W, Yeni GP, Staszewski S, Arasteh K, De Dier K, Peeters M, Woodfall B, Stebbing J, vant' Klooster GA. Gazzard BG, et al. AIDS. 2003 Dec 5;17(18):F49-54. doi: 10.1097/00002030-200312050-00001. AIDS. 2003. PMID: 14685068

2

Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance.

Walsh JC, Pozniak AL, Nelson MR, Mandalia S, Gazzard BG. Walsh JC, et al. Among authors: gazzard bg. J Acquir Immune Defic Syndr. 2002 Jul 1;30(3):278-87. doi: 10.1097/00126334-200207010-00003. J Acquir Immune Defic Syndr. 2002. PMID: 12131564

3

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.

Boffito M, Kurowski M, Kruse G, Hill A, Benzie AA, Nelson MR, Moyle GJ, Gazzard BG, Pozniak AL. Boffito M, et al. Among authors: gazzard bg. AIDS. 2004 Jun 18;18(9):1291-7. doi: 10.1097/00002030-200406180-00007. AIDS. 2004. PMID: 15362661

4

The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.

Sproat M, Pozniak AL, Peeters M, Winters B, Hoetelmans R, Graham NM, Gazzard BG. Sproat M, et al. Among authors: gazzard bg. Antivir Ther. 2005;10(2):357-61. Antivir Ther. 2005. PMID: 15865231

5

Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis.

Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG. Michailidis C, et al. Among authors: gazzard bg. Antivir Ther. 2005;10(3):417-22. doi: 10.1177/135965350501000303. Antivir Ther. 2005. PMID: 15918332

6

The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals.

Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, Stebbing J. Annan NT, et al. Among authors: gazzard bg. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):140-6. doi: 10.1097/QAI.0b013e3181a56e81. J Acquir Immune Defic Syndr. 2009. PMID: 19352201

7

The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapy.

Waters LJ, Scourfield AT, Marcano M, Gazzard BG, Bower M, Nelson M, Stebbing J. Waters LJ, et al. Among authors: gazzard bg. Clin Infect Dis. 2011 Mar 1;52(5):671-3. doi: 10.1093/cid/ciq198. Clin Infect Dis. 2011. PMID: 21292672

8

Clinical utility of resistance testing.

Stebbing J, Gazzard BG. Stebbing J, et al. Among authors: gazzard bg. J HIV Ther. 2002 Nov;7(4):75-9. J HIV Ther. 2002. PMID: 12733604 No abstract available.

9

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.

Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, Bower M, Johnson MA, Gazzard BG. Matthews GV, et al. Among authors: gazzard bg. AIDS. 2002 Jan 4;16(1):53-61. doi: 10.1097/00002030-200201040-00008. AIDS. 2002. PMID: 11741163 Clinical Trial.

10

Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma.

Powles T, Imami N, Nelson M, Gazzard BG, Bower M. Powles T, et al. Among authors: gazzard bg. AIDS. 2002 Mar 8;16(4):531-6. doi: 10.1097/00002030-200203080-00003. AIDS. 2002. PMID: 11872995

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

361 results

Search Page

Filters